The use of α-adrenoceptor antagonists in lower urinary tract disease

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Abstract

α-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to reduce irritative symptoms of the disease. Prazosin (Hypovase®, Alza), doxazosin (Cardura®, Pfizer), indoramin (Doralese®, Wyeth-Ayerst Pharmaceuticals Inc.) and terazosin (Hytrin®, Abbott Laboratories) are currently available in the UK for BPE but these agents have cardiovascular actions in a significant number of patients, inducing effects which must be considered adverse unless the patient also requires treatment for mild-to-moderate hypertension. The uroselective α-adrenoceptor antagonists tamsulosin (Flomax®, Yamanouchi Pharmaceutical Co. Ltd.) and alfuzosin (Xatral®, Sanofi-Synthelabo) have recently been introduced. These agents exert their selectivity via different mechanisms; selective tissue distribution for alfuzosin and α-adrenoceptor subtype selectivity for tamsulosin. The incidence of cardiovascular side effects for both drugs is similar to placebo. Several lines of evidence suggest that the α-adrenoceptor antagonists may relieve lower urinary tract (LUT) symptoms by other mechanisms additional to those which account for the reduction in bladder outlet obstruction. If correct, these agents may be of use in the treatment of other bladder conditions.

Original languageEnglish
Pages (from-to)167-172
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number2
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

tamsulosin
Urologic Diseases
Terazosin
Adrenergic Receptors
Doxazosin
Urinary Bladder Neck Obstruction
Indoramin
Hypertension
Cardiovascular Agents
Lower Urinary Tract Symptoms
Prazosin
Tissue Distribution
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Urinary Bladder
Placebos
Incidence
alfuzosin

Cite this

@article{f8bd79b2371c48e3b221e250a1ee6f21,
title = "The use of α-adrenoceptor antagonists in lower urinary tract disease",
abstract = "α-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to reduce irritative symptoms of the disease. Prazosin (Hypovase{\circledR}, Alza), doxazosin (Cardura{\circledR}, Pfizer), indoramin (Doralese{\circledR}, Wyeth-Ayerst Pharmaceuticals Inc.) and terazosin (Hytrin{\circledR}, Abbott Laboratories) are currently available in the UK for BPE but these agents have cardiovascular actions in a significant number of patients, inducing effects which must be considered adverse unless the patient also requires treatment for mild-to-moderate hypertension. The uroselective α-adrenoceptor antagonists tamsulosin (Flomax{\circledR}, Yamanouchi Pharmaceutical Co. Ltd.) and alfuzosin (Xatral{\circledR}, Sanofi-Synthelabo) have recently been introduced. These agents exert their selectivity via different mechanisms; selective tissue distribution for alfuzosin and α-adrenoceptor subtype selectivity for tamsulosin. The incidence of cardiovascular side effects for both drugs is similar to placebo. Several lines of evidence suggest that the α-adrenoceptor antagonists may relieve lower urinary tract (LUT) symptoms by other mechanisms additional to those which account for the reduction in bladder outlet obstruction. If correct, these agents may be of use in the treatment of other bladder conditions.",
author = "Russell Chess-Williams",
year = "2002",
doi = "10.1517/14656566.3.2.167",
language = "English",
volume = "3",
pages = "167--172",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare USA",
number = "2",

}

The use of α-adrenoceptor antagonists in lower urinary tract disease. / Chess-Williams, Russell.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 2, 2002, p. 167-172.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The use of α-adrenoceptor antagonists in lower urinary tract disease

AU - Chess-Williams, Russell

PY - 2002

Y1 - 2002

N2 - α-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to reduce irritative symptoms of the disease. Prazosin (Hypovase®, Alza), doxazosin (Cardura®, Pfizer), indoramin (Doralese®, Wyeth-Ayerst Pharmaceuticals Inc.) and terazosin (Hytrin®, Abbott Laboratories) are currently available in the UK for BPE but these agents have cardiovascular actions in a significant number of patients, inducing effects which must be considered adverse unless the patient also requires treatment for mild-to-moderate hypertension. The uroselective α-adrenoceptor antagonists tamsulosin (Flomax®, Yamanouchi Pharmaceutical Co. Ltd.) and alfuzosin (Xatral®, Sanofi-Synthelabo) have recently been introduced. These agents exert their selectivity via different mechanisms; selective tissue distribution for alfuzosin and α-adrenoceptor subtype selectivity for tamsulosin. The incidence of cardiovascular side effects for both drugs is similar to placebo. Several lines of evidence suggest that the α-adrenoceptor antagonists may relieve lower urinary tract (LUT) symptoms by other mechanisms additional to those which account for the reduction in bladder outlet obstruction. If correct, these agents may be of use in the treatment of other bladder conditions.

AB - α-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to reduce irritative symptoms of the disease. Prazosin (Hypovase®, Alza), doxazosin (Cardura®, Pfizer), indoramin (Doralese®, Wyeth-Ayerst Pharmaceuticals Inc.) and terazosin (Hytrin®, Abbott Laboratories) are currently available in the UK for BPE but these agents have cardiovascular actions in a significant number of patients, inducing effects which must be considered adverse unless the patient also requires treatment for mild-to-moderate hypertension. The uroselective α-adrenoceptor antagonists tamsulosin (Flomax®, Yamanouchi Pharmaceutical Co. Ltd.) and alfuzosin (Xatral®, Sanofi-Synthelabo) have recently been introduced. These agents exert their selectivity via different mechanisms; selective tissue distribution for alfuzosin and α-adrenoceptor subtype selectivity for tamsulosin. The incidence of cardiovascular side effects for both drugs is similar to placebo. Several lines of evidence suggest that the α-adrenoceptor antagonists may relieve lower urinary tract (LUT) symptoms by other mechanisms additional to those which account for the reduction in bladder outlet obstruction. If correct, these agents may be of use in the treatment of other bladder conditions.

UR - http://www.scopus.com/inward/record.url?scp=0036170158&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.2.167

DO - 10.1517/14656566.3.2.167

M3 - Article

VL - 3

SP - 167

EP - 172

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -